SHC Sotera Health

Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025.

Mr. Petrella, who has served on Sotera Health Company’s Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company’s strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders.

Mr. Petrella has decades of public company executive leadership and board experience. “Since joining our Board, Vince’s experience, insight and engagement have been invaluable as chairperson of our Audit Committee. We are delighted to benefit from his continued knowledge and guidance as our Lead Independent Director,” said Michael B. Petras, Jr., Sotera Health Chairman and Chief Executive Officer.

“It is a great privilege to engage with Sotera Health leadership and the Board, and I’m excited by this opportunity to lead in an expanded way,” Mr. Petrella said. “I appreciate the confidence of the Board and look forward to continuing to support Sotera Health and drive shareholder value.”

About Vincent K. Petrella

Mr. Petrella served as the Executive Vice President, Chief Financial Officer and Treasurer at Lincoln Electric Holdings, Inc., a welding, cutting and brazing products manufacturer from 2004 until April 2020. He is currently a board member of Applied Industrial Technologies, Inc. and the Gorman-Rupp Company.

About Sotera Health

Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at . For developments related to Ethylene Oxide, updates can be found at .

INVESTOR RELATIONS CONTACT

Jason Peterson

Vice President, Investor Relations & Treasurer

MEDIA CONTACT

Kristin Gibbs

Chief Marketing Officer

Source: Sotera Health Company



EN
06/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sotera Health

 PRESS RELEASE

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Secondary Offering of Common Stock CLEVELAND, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 30,000,000 shares of its common stock, par value $0.01 per share. All 30,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not ...

 PRESS RELEASE

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Resul...

Sotera Health Reports Strong Third-Quarter and Year-to-Date 2025 Results Q3 2025 net revenues increased 9.1% to $311 million, or 8.0% on a constant currency basis(1), compared to Q3 2024Q3 2025 net income of $48 million, or $0.17 per diluted share, compared to net income of $17 million or $0.06 per diluted share in Q3 2024Q3 2025 Adjusted EBITDA(1) increased 12.2% to $164 million, or 11.2% on a constant currency basis, compared to Q3 2024Q3 2025 Adjusted EPS(1) of $0.26, an increase of $0.09 per diluted share, compared to Adjusted EPS of $0.17 in Q3 2024Raising 2025 Adjusted EBITDA growth r...

 PRESS RELEASE

Sotera Health Announces Third-Quarter 2025 Earnings Release Date

Sotera Health Announces Third-Quarter 2025 Earnings Release Date CLEVELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the third-quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company’s financial results and oper...

 PRESS RELEASE

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Announces Secondary Offering of Common Stock CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value $0.01 per share. All 20,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. The Company is not offering any shares in the Offering and will not...

 PRESS RELEASE

Sotera Health Reports Strong Second-Quarter and First-Half 2025 Result...

Sotera Health Reports Strong Second-Quarter and First-Half 2025 Results Q2 2025 net revenues increased 6.4% to $294 million, or 6.0% on a constant currency basis(1), compared to Q2 2024Q2 2025 net income of $8 million or $0.03 per diluted share, compared to net income of $9 million or $0.03 per diluted share in Q2 2024Q2 2025 Adjusted EBITDA(1) increased 9.8% to $151 million, or 9.5% on a constant currency basis, compared to Q2 2024Q2 2025 Adjusted EPS(1) of $0.20, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.19 in Q2 2024Raising both full-year 2025 net revenues ou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch